Cargando…

Availability of Investigational Medicines Through the US Food and Drug Administration’s Expanded Access and Compassionate Use Programs

IMPORTANCE: The Right to Try Act of 2017 allows patients with life-threatening conditions to access investigational medicines outside clinical trials without oversight from the US Food and Drug Administration (FDA). A better understanding of existing expanded access programs can inform the considera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puthumana, Jeremy, Miller, Jennifer E., Kim, Jeanie, Ross, Joseph S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2018
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324420/ https://www.ncbi.nlm.nih.gov/pubmed/30646072 http://dx.doi.org/10.1001/jamanetworkopen.2018.0283

Ejemplares similares

Characterizing expanded access and compassionate use programs for experimental drugs
por: Miller, Jennifer E., et al.
Publicado: (2017)

Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017
por: Zhang, Audrey D., et al.
Publicado: (2020)

Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera, et al.
Publicado: (2021)

Slum compassionate community: expanding access to palliative care in Brazil
por: Mesquita, Maria Gefé da Rosa, et al.
Publicado: (2023)

Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010–2020
por: Zhang, Audrey D., et al.
Publicado: (2021)

Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration
por: Egilman, Alexander, et al.
Publicado: (2021)

Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
por: Rizk, John G., et al.
Publicado: (2021)

Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021
por: Maeda, Hideki, et al.
Publicado: (2022)

Availability of Family Caregiver Programs in US Cancer Centers
por: Odom, J. Nicholas, et al.
Publicado: (2023)

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
por: Modi, Natansh D., et al.
Publicado: (2022)

Compassionate Off-Ramps: The Availability of Terminal Master's Degrees in US Medical Schools
por: Petersen, Kristina H, et al.
Publicado: (2023)

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
por: de la Rubia, Javier, et al.
Publicado: (2023)

An Evaluation of US Food and Drug Administration’s Program to Register HIV Drugs for Use in Resource-Constrained Settings
por: Chahal, Harinder Singh, et al.
Publicado: (2019)

US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018
por: Omae, Kenji, et al.
Publicado: (2022)

Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs
por: Gould, Patrick, et al.
Publicado: (2022)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration
por: Sankar, Ashwini, et al.
Publicado: (2021)

International Country-Level Trends, Factors, and Disparities in Compassionate Use Access to Unlicensed Products for Patients With Serious Medical Conditions
por: Aliu, Paul, et al.
Publicado: (2022)

Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021
por: Daval, C. Joseph Ross, et al.
Publicado: (2023)

Applying real-world data from expanded-access (“compassionate use”) patients to drug development
por: Wasser, June S., et al.
Publicado: (2023)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Availability of New Medicines in the US and Germany From 2004 to 2018
por: Blankart, Katharina, et al.
Publicado: (2022)

Noncommercial US Funders’ Policies on Trial Registration, Access to Summary Results, and Individual Patient Data Availability
por: Whitlock, Evelyn P., et al.
Publicado: (2019)

Taking AIM at serious illness: implementing an access to investigational medicines expanded access program
por: Joly, Meghan Morrison, et al.
Publicado: (2023)

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
por: Skydel, Joshua J., et al.
Publicado: (2019)

Substance Use Disorder Program Availability in Safety-Net and Non–Safety-Net Hospitals in the US
por: Chang, Ji E., et al.
Publicado: (2023)

Right now, in the right way: U. S. Food and Drug Administration’s expanded access program and patient rights
por: Holbein, M. E. Blair, et al.
Publicado: (2018)

Geographic Accessibility and Availability of Radiotherapy in Ghana
por: Scott, Aba Anoa, et al.
Publicado: (2022)

Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021
por: Monge, Andrea N., et al.
Publicado: (2022)

Time From Authorization by the US Food and Drug Administration to Medicare Coverage for Novel Technologies
por: Sexton, Zachary A., et al.
Publicado: (2023)

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022)

Supplemental Nutrition Assistance Program Access and Racial Disparities in Food Insecurity
por: Samuel, Laura J., et al.
Publicado: (2023)

Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia
por: Rubino, Annalisa, et al.
Publicado: (2020)

Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings
por: Tucker, Jenna, et al.
Publicado: (2018)

Varenicline and Nicotine Replacement Use Associated With US Food and Drug Administration Drug Safety Communications
por: Desai, Ravi J., et al.
Publicado: (2019)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
por: Sachs, Rachel E., et al.
Publicado: (2021)

The BC Cancer Agency Compassionate Access Program: outcome analysis of patients with esophagogastric cancer
por: Wilson, K.S., et al.
Publicado: (2009)

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
por: Skydel, Joshua J., et al.
Publicado: (2022)

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gh33c7vdff207m3llkjq8u50fe